Journal Article

Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study

Komori, Koji, Yamada, Takeshi, Arakaki, Junya, Ishihara, Soichiro, Okuda, Junji, Akagi, Yoshito, Nakamura, Masafumi, Yamamoto, Takayuki, Matsuda, Keiji, Kazama, Shinsuke, Yamada, Kazutaka, Ueno, Hideki, Ohge, Hiroki, Daito, Koji, Ogino, Takayuki, Goi, Takenori, Sugihara, Kenichi, Sunami, Eiji, Toiyama, Yuji, Seishima, Ryo, Kinugasa, Yusuke, Kiyomatsu, Tomomichi, Kanemitsu, Yukihide, Uehara, Kei, Okabayashi, Koji, Ikeuchi, Hiroki, Hasegawa, Junichi, Hida, Koya, Noguchi, Tatsuki, Yamaguchi, Shigeki, Uchino, Motoi, Hanai, Tsunekazu, Katsumata, Kenji, Ajioka, Yoichi, Kimura, Hideaki, Itabashi, Michio, Takahashi, Kenichi, Maemoto, Atsuo, Sasaki, Shin, Noake, Toshihiro, Okamoto, Kinya, Koyama, Fumikazu, Futami, Kitaro, Shida, Dai, Suto, Takeshi, Iseki, Yasuhito, Nezu, Riichiro, Ishida, Fumio, Yamamoto, Seiichiro, Sato, Yu, Wakai, Toshifumi, Watanabe, Kazuhiro, Maeda, Kiyoshi

2023

Overview

The aim of this study was to evaluate the effect of biologics on the risk of advanced-stage inflammatory bowel disease (IBD)-associated intestinal cancer from a nationwide multicenter data set. The medical records of patients with Crohn's disease (CD) and ulcerative colitis (UC) diagnosed with IBD-associated intestinal neoplasia (dysplasia or cancer) from 1983 to 2020 were included in this study. Therapeutic agents were classified into 3 types: biologics, 5-aminosalicylic acid, and immunomodulators. The pathological cancer stage was compared based on the drug used in both patients with CD and UC. In total, 1,042 patients (214 CD and 828 UC patients) were included. None of the drugs were significantly associated with cancer stage in the patients with CD. In the patients with UC, an advanced cancer stage was significantly associated with less use of biologics (early stage: 7.7% vs advanced stage: 2.0%, P < 0.001), 5-aminosalicylic acid, and immunomodulators. Biologic use was associated with a lower incidence of advanced-stage cancer in patients diagnosed by regular surveillance (biologics [-] 24.5% vs [+] 9.1%, P = 0.043), but this was not the case for the other drugs. Multivariate analysis showed that biologic use was significantly associated with a lower risk of advanced-stage disease (odds ratio = 0.111 [95% confidence interval, 0.034-0.356], P < 0.001). Biologic use was associated with a lower risk of advanced IBD-associated cancer in patients with UC but not with CD. The mechanism of cancer progression between UC and CD may be different and needs to be further investigated.

• Publisher: Wolters Kluwer,Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
• Subject: Biological products / Biological Products - therapeutic use / Cancer / Colitis, Ulcerative - complications / Colitis, Ulcerative - diagnosis / Colitis, Ulcerative - drug therapy / Colon / Colorectal cancer / Crohn Disease - complications / Crohn Disease - diagnosis / Crohn Disease - drug therapy / Crohn's disease / Diagnostic tests / Endoscopy / Gastroenterology / Health surveillance / Humans / Immunologic Factors - therapeutic use / Inflammation / Inflammatory bowel disease / Inflammatory Bowel Diseases - complications / Inflammatory Bowel Diseases - diagnosis / Inflammatory Bowel Diseases - drug therapy / Intestinal Neoplasms - complications / Mesalamine - therapeutic use / Multivariate analysis / Patients / Rectum / Steroids / Tumor necrosis factor-TNF